January 27, 2023

CMND PROFILE

OUR NEW PROFILE IS:   (NASDAQ: CMND)

__________

CMND trades in Canada (CSE: CMND) as well as Germany (FWB: CWY)

READ THE INVESTOR PRESENTATION HERE

_______________________

Hello Everyone,

We have another exciting profile for you for for today’s session.  This one operates in a unique, niche sector with a bright future ahead of it. With a recent uplisting to the NASDAQ, Clearmind Medicine, Inc. (NASDAQ: CMND) is a company to look at closely! The world is in a mental health crisis, with near all-time level highs of depression, PTSD, anxiety, and addiction. The pandemic has negatively affected many people, impacting their mental health on many levels. The current mental health treatments available, such as SSRIS for depression and rehab for addiction, may be effective, but also leave far too many people behind. Plus, the treatment for these conditions is massive, raking in billions of dollars a year, even if they aren’t effective. There needs to be a solution and the growing psychedelics movement might be it. Early scientific evidence is showing that treatments such as MDMA therapy for PTSD, psilocybin therapy for depression, and ketamine therapy for addictions, are much more effective than current treatments!

Are we looking at another sector before it goes mainstream.  We all know how many millionaires were made from trading MJ companies made trading these things early on.  It is certainly worth noting that voters passed the 2020 Oregon Ballot Measure 109, making it the first state to both decriminalize psilocybin and also legalize it for therapeutic use. Colorado followed with the 2022 Colorado Ballot Measure 122.

 

 

A report  from Data Bridge Market Research estimates that the global psychedelic drugs market will reach $6.4 billion by 2029. Such an expansion would mean a compounded annual growth rate (CAGR) of well over 13% between 2022 and 2029. Clearmind Medicine, Inc. (NASDAQ: CMND)  is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

CATALYSTS

Clearmind’s flagship treatments are focused on Alcohol Use Disorder (AUD), which is incredibly common. It varies from mild to excessive, and describes a person’s inability to restrict their alcohol consumption, despite negative social, occupational, or health consequences.

  • Alcohol consumption is the 3rd leading preventable cause of death in the US.
  • The yearly cost of excessive alcohol use in the US reached $249Bn in 2010.
  • Alcohol consumption contributes to 3 million deaths each year globally… In addition to disabilities and poor health of millions of people. – World Health Organization

—–

The Solution: MEAI (5-Methoxy-2-aminoindane)

5-Methoxy-2-aminoindane (MEAI) is a psychoactive molecule, exerting a euphoric alcohol-like experience and a reduced desire to consume alcoholic beverages. It shows a good safety profile in pre-clinical studies, with potential to change the lives of millions who struggle to drink in moderation.

Breaking the Cycle

We believe that MEAI breaks the vicious binge-drinking cycle at the decision point to drink more alcohol, by potentially innervating neural pathways such as 5-HT1A that lead to “sensible behaviour.”

Non-Addictive

Anecdotal reports and pre-clinical in-vivo results indicate the self-limiting property of MEAI—unlike traditional treatments.

Expansive Potential

The literature shows that 5-HT1A receptors are associated with controlling craving behavior across the board. This indicates that MEAI may have a wide range of applications beyond binge drinking.

—–

Successful Pre-clinical Results In MEAI Treatment For Alcohol Consumption

Pre-clinical trial demonstrated a high safety profile in addition to a significant suppressive effect on alcohol consumption.

  • Clearmind conducted preclinical trials, training groups of mice to consume alcohol for five weeks
  • The groups were then given a daily dose of MEAI, with intermittent access to alcohol and water
  • After two weeks, researchers found a significant reduction in alcohol consumption in mice receiving MEAI
  • The untreated control group showed no significant reduction in alcohol consumption
  • No SAEs or treatment-related histological changes were observed amongst all MEAI treatment groups compared to control naive and vehicle animals in all the examined organs

Low Competitive Intensity

Only 3 other psych-e-delic companies are working on alcohol abuse problems:

The Company’s Competitive Advantage

Most companies in the psych-e-delics field target depression and anxiety.

Clearmind focuses on binge behaviors and addictions: A huge untapped market

Most companies develop classic psych-e-delics for which intellectual property is hard to file and approve.

Clearmind is the sole developer of MEAI and has a robust portfolio of protected intellectual property

Most psych-e-delic treatments are designed to be adjuncts to psychotherapy.

MEAI is designed to be self administered, due to its high safety potential, and not in conjunction to psychotherapy

—–

Expected Timeline:

Clearmind Announces Initiation of CMND-100 Manufacturing Program to Address its Upcoming Clinical Trial

VANCOUVER, November 23, 2022 — Clearmind Medicine Inc. (Nasdaq: CMND), (CSE: CMND), (FSE: CWY) (“Clearmind” or the “Company“), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced the initiation of clinical batches of production of its novel psychedelic-derived drug candidate, the MEAI-based molecule- CMND-100.

The produced batches will be used in the Company’s upcoming first in human (FIH) clinical trial evaluating the proprietary drug candidate compound CMND-100 for the treatment of Alcohol Use Disorder (AUD).

Following MEAI’s synthesis development process, the compound is being produced under GMP (Good Manufacturing Process) conditions to comply with FDA requirements. The clinical batches production is made possible due to prior successful production of MEAI drug substance that was used in the Company’s pre-clinical studies designed to evaluate the safety of its innovative compound.

“Clearmind continues its progress toward FIH clinical trial” said Dr. AdiZuloff-Shani, Clearmind’s Chief Executive Officer. “This milestone joins other achievements we’ve made in a relatively short period.  Non-clinical data generated to date, demonstrate that our MEAI- based treatment has the potential to treat broad range of addictions and binge behaviors such as AUD.”

“Like other addictions, AUD is a chronic relapsing brain disorder characterized by an impaired ability to stop or control alcohol use,” she added. “Alcohol abuse is the third most-common preventable cause of death in the United States, where almost 6% struggle with this condition. ”

The Company previously announce that it completed a highly constructive Pre-Investigational New Drug Application (“pre-IND”) meeting with the U.S. Food and Drug Administration (“FDA”) to discuss the development of CMND-100.

Clearmind Applies for Patent to Treat Obesity and Metabolic Syndrome

Patent Application, Based on Research at the Hebrew University, is Latest Result of Ongoing Collaboration with SciSparc Ltd.

VANCOUVER, Sept. 22,2022 — Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“Clearmind” or the “Company“), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced it has filed a provisional patent application related to metabolic syndromes including obesity.

The patent application is another result of the company’s ongoing collaboration with SciSparc Ltd.(NASDAQ: SPRC) (“SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, and with the Hebrew University of Jerusalem.

The patent application is the third application resulting from the collaboration with SciSparc, referring to the proprietary combination of Clearmind’s MEAI, a novel proprietary psychedelic treatment for various addictions, and SciSparc’s Palmitoylethanolamide (PEA), the active ingredient of its proprietary CannAmide™, which is used for treating obesity and its related metabolic disorders.

“Food addiction and obesity are an epidemic raging in the United States and around the world, yet there are few safe and effective anti-obesity treatments on the market,”said Dr. Adi Zuloff-Shani, Clearmind’s Chief Executive Officer.

“In pre-clinical studies MEAI has shown great potential in its ability to treat different addictions. Certain metabolic syndromes can be associated to addictive behaviors, and we believe combining MEAI with SciSparc’s CannAmide™ may create a valuable tool for treating these conditions.”

The study was conducted as part of Clearmind’s research and development projects with the Hebrew University’s Obesity and Metabolism Laboratory, which is led by Joseph Tam,D.M.D., Ph.D., Associate Professor of Pharmacology at the University’s Institute for Drug Research.

“This new patent application continues Clearmind’s strategy since inception to enhance its IP portfolio to create state-of-the-art psychedelic drug candidates, to better serve patients in need,” said Dr. Zuloff-Shani.

Clearmind Medicine Announces Positive Pre-Clinical Results for Cocaine Addiction Treatment

The dedicated treatment demonstrated a significant decrease in preference for an area associated with cocaine

VANCOUVER, June 7, 2022–Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“Clearmind” or the “company“), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced positive pre-clinical results for its treatment for cocaine addiction using MEAI, its novel psychedelic molecule.

“This exciting research on MEAI could go a long way in helping those who need it,” said Dr. Adi Zuloff-Shani, Clearmind’s ChiefExecutive Officer. “While effective treatments for opioid addictions have been available, this could be the first dedicated treatment for cocaine addiction, which is a global crisis.”

 

The pre-clinical trial, led by Professor Gal Yadid and his team, from the Gonda Multidisciplinary Brain Research Center located at Bar Ilan University (RamatGan, Israel), was designed to evaluate possible reward-like effects of MEAI, on male Sprague-Dawley rats based on the Conditioned Place Preference (CPP*)model.

 

Rats previously conditioned with cocaine received either cocaine (at 15mg/kg) or MEAI at doses of 2.5, 5, 10 and 20 mg/kg. Rats treated with MEAI spent less time in the compartment associated with cocaine. Results suggest a potential role for MEAI in abolishing cocaine-induced conditioned place preference and eliminating heightened craving, and that the compound was not itself addictive.The 5 mg/kg dose was found the most effective dose and selected for further study.

 

The results followed Clearmind’s recent news regarding filing a provisional patent application related to cocaine addiction.

 

“Once again, MEAI has shown the potential to become a game changer in the field of addiction treatments” Zuloff- Shani added.”We intend to further explore the potential of MEAI as an anti-cocaine addiction treatment.”

*A testing method by which the animals learned to associate between reward and an environmental cue

 

MANAGEMENT

NEWS

23

November

Clearmind Announces Initiation of CMND-100 Manufacturing Program to Address its Upcoming Clinical Trial

Read More

17

November

Clearmind Medicine Announces Closing of US$7.5 Million Public Offering and Uplisting to the Nasdaq Capital Market

Read More

11

October

Clearmind Medicine Featured in “Psychedelics Tonight,” Streaming on ALTRD.TV

Read More

22

September

Clearmind Applies for Patent to Treat Obesity and Metabolic Syndrome

Read More

24

August

Clearmind Medicine Announces Additional Positive Pre-Clinical Results for its Cocaine Addiction Treatment

Read More

21

June

Yale’s Department of Psychiatry Chair to Join Clearmind Medicine

Read More

15

June

Clearmind Medicine Appoints New Chief Financial Officer

Read More

7

June

Clearmind Medicine Announces Positive Pre-Clinical Results for Cocaine Addiction Treatment

Read More

2

June

Clearmind Medicine and SciSparc Collaboration Yields Another Patent Application for Cocaine Addiction Treatment

Read More

 

Sincerely,

The Viral Stocks Team

DISCLAIMER

 

THIS WEBSITE/NEWSLETTER IS A WHOLLY OWNED SUBSIDIARY OF GLOBAL COIN MEDIA, LLC.  HEREIN REFERRED TO AS GCM, LLC.  WE ARE A NEVADA COMPANY. 
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION.  WE  HAVE  BEEN COMPENSATED A FEE OF TEN THOUSAND USD BY A THIRD PARTY, LEGENDS MEDIA, LLC FOR A ONE DAY CMND AWARENESS CAMPAIGN.  NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: GCMLLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD GCM, LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. GCMLLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND GCM, LLCMAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD GCM, LLC.  STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.GCM, LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. GCM, LLCDOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND GCM, LLCFURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS.IN PREPARING THIS PUBLICATION,GCM, LLCHAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, GCM, LLCAND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. GCM, LLCIS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS GCM, LLCRESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. GCM, LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.